MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 31, 2007; DOI: 10.1124/mol.107.036772


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.107.036772v1
72/5/1111    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mai, A.
Right arrow Articles by Migliaccio, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mai, A.
Right arrow Articles by Migliaccio, G.


Received for publication April 5, 2007.
Revised July 25, 2007.
Accepted for publication July 25, 2007.

Identification of two New Synthetic Histone Deacetylase Inhibitors that Modulate Globin Gene Expression in Erythroid Cells from Normal Donors and Thalassemic Patients

Antonello Mai 1, Katija Jelicic 2, Dante Rotili 1, Antonella Di Noia 2, Elena Alfani 2, Sergio Valente 1, Lucia Altucci 3, Angela Nebbioso 3, Silvio Massa 4, Renzo Galanello 5, Gerald Brosch 6, Anna Rita Migliaccio 2*, Giovanni Migliaccio 2

1 Universita di Roma La Sapienza 2 Istituto Superiore di Sanita 3 Seconda Universita di Napoli 4 Universita di Siena 5 Universita di Cagliari 6 Innsbruck Medical University

* Address correspondence to: E-mail: migliar{at}iss.it

Abstract

We have identified two new histone deacetylase (HDAC) inhibitors (9 and 24) capable to induce the expression of g-globin and/or {gamma}-globin promoter-driven reporter genes in a synthetic model of Hb switch. Both compounds also increased, with different mechanisms, the {gamma}/({gamma}+{beta}) ratio expressed in vitro by normal human erythroblasts. Compound 9, increased the levels of {gamma}-globin mRNA, and the {gamma}/({gamma}+{beta}) ratio (both by 2-fold). Compound 24, increased by 3-fold the level of {beta}-globin and decreased by 2-fold that of {beta}-globin mRNA, increasing the {gamma}/({gamma}+{beta}) ratio by 6-fold, and raising (by 50%) the cell HbF content. Both compounds raised the acetylation state of histone H4 in primary cells, an indication that their activity was mediated through HDAC inhibition. Compound 9 and 24 were also tested as {gamma}/({gamma}+{beta}) mRNA inducers in erythroblasts obtained from {beta}0-thalassemic patients. Progenitor cells from {beta}0-thalassemic patients generated in vitro morphologically normal pro-erythroblasts that, unlike normal cells, failed to mature in the presence of EPO and expressed low {beta}-globin levels, but levels of the alpha hemoglobin stabilizing protein (AHSP) mRNA 10-times higher than normal. Both compounds ameliorated the impaired in vitro maturation in {beta}0-thalassemic erythroblasts decreasing AHSP expression down to normal levels. In the case of two patients (out of 5 analyzed), the improved erythroblast maturation was associated with detectable increases in the {gamma}/({gamma}+{beta}) mRNA ratio. The low toxicity exerted by compounds 9 and 24 in all of the assays investigated suggests that these new HDAC inhibitors should be considered for personalized therapy of selected {beta}0-thalassemic patients.


Key words: Regulation of gene expression, Regulation - post-transcriptional, Regulation - transcriptional, Transcription targets





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics